Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Syndax Highlights Revuforj Post-Transplant and PK Data at ASCO 2026

Syndax Pharmaceuticals announced the acceptance of four Revuforj (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Key presentations include an oral presentation highlighting favorable outcomes in 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant. Additionally, a poster will detail revumenib's pharmacokinetic profile, emphasizing its compatibility with gastric acid reducing agents and low-fat meals, and a clear dose adjustment strategy for strong CYP3A4 inhibitors. The company will also present designs for ongoing pivotal Phase 3 trials.

• The oral presentation (Abstract 6505) will showcase safety and efficacy data from 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib as maintenance following hematopoietic stem cell transplantation (HSCT). This presentation will include observed overall survival and relapse rates, along with a comparison to a historical cohort, providing crucial evidence for post-transplant management.
• A poster presentation (Abstract 6528) will characterize the pharmacokinetics (PK) of revumenib, highlighting its unique profile. This includes the ability to administer revumenib with gastric acid reducing agents without reducing efficacy, a clear dose adjustment strategy for optimal exposure in the presence of strong CYP3A4 inhibitors, and its compatibility with low-fat meals, offering important practical guidance for clinicians.
• Syndax will also present 'Trial in progress' abstracts for two ongoing Phase 3 studies: EVOLVE-2 (revumenib plus venetoclax/azacitidine in newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy) and REVEAL-ND NPM1 (revumenib in combination with intensive chemotherapy in newly diagnosed NPM1-mutated acute myeloid leukemia), outlining future directions for the drug's development.

Revuforj's Favorable Outcomes in Post-Transplant Acute Leukemia

Recent studies have demonstrated significant advancements in acute leukemia treatment, particularly with venetoclax-based combinations and targeted therapies. A 2025 retrospective analysis of 90 treatment-naive elderly AML patients compared 14-day versus 28-day venetoclax plus azacitidine regimens, revealing comparable clinical remission rates (57.4% vs 58.1%, P=0.947) with no significant differences in median overall survival or event-free survival. However, the 14-day cohort demonstrated superior safety outcomes, including significantly faster neutrophil recovery (median 12.5 vs 26 days, P<0.01) and reduced febrile neutropenia (73.3% vs 90.9%, P<0.05). A separate target trial emulation study using propensity score matching confirmed that venetoclax plus hypomethylating agents conferred superior overall survival compared to hypomethylating agents alone in elderly patients ≥60 years, with particularly prominent benefits in patients ≥75 years old.

Transplant conditioning regimens have also shown promising results in real-world settings. A 2026 retrospective analysis of 66 patients with AML and MDS evaluated treosulfan-fludarabine with or without thiotepa intensification for allogeneic hematopoietic stem cell transplant. Despite a patient population with median age 67 years and 56% having hematopoietic cell transplantation-comorbidity index >2, the study achieved encouraging outcomes with 3-year overall survival of 52%, progression-free survival of 46%, and nonrelapse mortality of only 18%. Safety profiles were acceptable, with 100-day cumulative incidence of grade ≥2 acute graft-versus-host disease at 34% and 3-year moderate-to-severe chronic graft-versus-host disease at 21%.

Salvage therapy optimization has emerged as another critical area of investigation. A 2026 multicenter retrospective analysis comparing CLAG regimen with cytarabine doses of 1 g/m² versus 2 g/m² in 183 relapsed/refractory AML patients demonstrated significantly higher complete response rates with the higher dose (71.9% vs 53.7%, p=0.013) and superior 2-year overall survival (46.2% vs 13.4%, p=0.004). The higher dose regimen showed similar toxicity profiles except for longer neutropenia duration (18 vs 16 days, p=0.003), without increases in significant toxicity. These findings highlight the importance of dose optimization in salvage settings while maintaining acceptable safety profiles.

Optimizing Revuforj Administration: PK Insights from ASCO

Revumenib demonstrated a manageable safety profile across clinical studies, with treatment-related adverse events leading to discontinuation in only 4.8% of patients in the AUGMENT-101 study. The safety data was consistent across different patient populations with predictable and acceptable toxicities. Grade ≥3 adverse events and key safety considerations include several distinct toxicity patterns.

• Hematologic toxicities: Febrile neutropenia was the most common grade ≥3 adverse event, occurring in 37.2% of patients in the AUGMENT-101 study

• Differentiation syndrome: This key toxicity associated with menin inhibitors occurred in 10-25% of patients with KMT2A-rearranged or NPM1-mutated AML, representing 16.0% of grade ≥3 events

• Cardiac toxicities: QTc prolongation was identified as a significant toxicity, occurring as a grade ≥3 event in 13.8% of patients

• Treatment discontinuation rate: Treatment-related adverse events led to discontinuation in 4 patients (4.8%) in the NPM1-mutated AML cohort of 84 patients who received ≥1 dose

• Cross-study consistency: The safety profile remained consistent with previously reported results across different patient populations and study phases

• Resistance patterns: Early resistance emergence was observed, primarily through MEN1 mutations appearing as early as two treatment cycles, though this represents an efficacy rather than safety concern

Advancing Revuforj: Phase 3 Trials in Newly Diagnosed AML

Recent acute leukemia trials demonstrate evolving approaches to study design, incorporating biomarker stratification, multiomics analyses, and refined endpoint selection. These studies span from early-phase dose-finding trials to large retrospective analyses, reflecting the field's progression toward precision medicine approaches and improved prognostic modeling.

Revuforj: Charting a Course for Broader Acute Leukemia Impact

The upcoming ASCO presentations for Revuforj (revumenib) underscore a pivotal moment for precision medicine in acute leukemia, particularly for patients with KMT2A-rearranged (KMT2Ar), NPM1-mutated (NPM1m), or NUP98-rearranged disease. As a recently FDA-approved, first-in-class menin inhibitor, revumenib has already demonstrated promising efficacy in heavily pretreated, relapsed or refractory (R/R) settings, achieving meaningful remission rates and high measurable residual disease (MRD) negativity. The new data, especially the favorable outcomes in post-transplant patients, signals a strategic expansion of its therapeutic potential. This suggests revumenib could play a crucial role in preventing relapse or as a maintenance therapy, addressing a significant unmet need in these high-risk populations where long-term disease control remains challenging.

Furthermore, the detailed pharmacokinetic profile, confirming compatibility with common gastric acid reducing agents and low-fat meals, along with clear dose adjustment guidelines for strong CYP3A4 inhibitors, is not merely scientific detail. It represents a practical enhancement for clinicians, simplifying administration and potentially improving patient adherence, thereby facilitating broader real-world adoption. The company's announcement of ongoing pivotal Phase 3 trial designs clearly indicates an ambition to move beyond the R/R setting, exploring revumenib's utility in earlier lines of therapy or as part of combination regimens, aiming to establish it as a new standard of care.

However, this promising trajectory is not without its considerations. The literature highlights the emergence of resistance mechanisms, such as acquired MEN1 mutations and de novo TP53 mutations, which can limit the durability of monotherapy responses. Managing the known adverse events, particularly QTc prolongation and differentiation syndrome, will remain critical, especially as the drug is integrated into more complex combination strategies. Moreover, the burgeoning pipeline of other menin inhibitors suggests an increasingly competitive landscape, necessitating continuous innovation and robust clinical differentiation for revumenib to maintain its leadership position. Ultimately, these presentations reinforce the menin inhibitor class as a transformative force in acute leukemia, but also emphasize the ongoing need for strategic development to maximize patient benefit and navigate evolving challenges.